Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer

1. Schneeweiss, A.
2. Chia, S.
3. Hickish, T.
4. Harvey, V.
5. Eniu, A.
6. Waldron-Lynch, M.
7. Eng-Wong, J.
8. Kirk, S.
9. Cortés, J.